Certain Breast Cancer Patients Can Safely Forgo Axillary Surgery
Breast cancer patients without axillary lymph node involvement who have tumors no larger than 2 cm can safely forgo axillary surgery, a phase 3 trial suggests.
All articles by Andrea S. Blevins Primeau, PhD, MBA
HIPEC Improves Long-Term Outcomes in Stage III Ovarian Cancer
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
Dabrafenib Plus Trametinib Bests Chemo in Kids With BRAF-Mutant Glioma
First-line treatment with dabrafenib and trametinib can improve outcomes, when compared to standard chemotherapy, in children with BRAFV600-mutated low-grade glioma, a phase 2 trial suggests.
Breast Cancer Detected in Breast Milk Earlier Than in Plasma
Researchers say they have detected breast cancer in ctDNA from breast milk, and breast milk may allow for earlier cancer detection than plasma.
Air Pollution Linked to Increased Risk of Breast Cancer
Long-term historical exposure to air pollution is associated with an increased risk of breast cancer, a new study suggests.
Patients With HER2+ Metastatic CRC Aren’t Receiving Guideline-Concordant Care
Data suggest that many patients with HER2+, metastatic colorectal cancer do not receive HER2-targeted therapy as recommended by NCCN guidelines.
Cancer Deaths Increased During the First 2 Years of the COVID-19 Pandemic
Cancer deaths increased during the first 2 years of the COVID-19 pandemic in the United States, a population-based study suggests.
7-8 Years of Adjuvant Endocrine Therapy Deemed Sufficient in Postmenopausal Breast Cancer
Taking adjuvant endocrine therapy for 7 to 8 years is likely sufficient for maximal disease-free survival benefits among most postmenopausal women with HR+ breast cancer, according to researchers.
Intervention Enables Same-Day Genetic Testing for Ovarian Cancer Patients
A genetic testing station can increase uptake and improve the efficiency of genetic testing for patients with ovarian cancer, a study suggests.
Adding Ipilimumab to Nivolumab Doesn’t Provide Meaningful Benefit, Researchers Say
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...